Literature DB >> 30613602

Surrogate study endpoints in the era of cancer immunotherapy.

Tsuyoshi Hamada1,2, Keisuke Kosumi2,3, Yousuke Nakai1, Kazuhiko Koike1.   

Abstract

Entities:  

Year:  2018        PMID： 30613602      PMCID： PMC6291549          DOI： 10.21037/atm.2018.09.31

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  The validation of surrogate endpoints in meta-analyses of randomized experiments.

Authors:  M Buyse; G Molenberghs; T Burzykowski; D Renard; H Geys
Journal:  Biostatistics       Date:  2000-03       Impact factor: 5.899

2.  Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.

Authors:  Kent R Johnson; Clare Ringland; Barrie J Stokes; Danielle M Anthony; Nick Freemantle; Alar Irs; Suzanne R Hill; Robyn L Ward
Journal:  Lancet Oncol       Date:  2006-09       Impact factor: 41.316

3.  Toward progression-free survival as a primary end point in advanced colorectal cancer.

Authors:  Greg Yothers
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 4.  Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

Authors:  Patricia A Tang; Søren M Bentzen; Eric X Chen; Lillian L Siu
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

5.  Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.

Authors:  Carine A Bellera; Marina Pulido; Sophie Gourgou; Laurence Collette; Adélaïde Doussau; Andrew Kramar; Tienhan Sandrine Dabakuyo; Monia Ouali; Anne Auperin; Thomas Filleron; Catherine Fortpied; Christophe Le Tourneau; Xavier Paoletti; Murielle Mauer; Simone Mathoulin-Pélissier; Franck Bonnetain
Journal:  Eur J Cancer       Date:  2012-11-02       Impact factor: 9.162

6.  Methods for adjusting for bias due to crossover in oncology trials.

Authors:  K Jack Ishak; Irina Proskorovsky; Beata Korytowsky; Rickard Sandin; Sandrine Faivre; Juan Valle
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Progression-free survival is a surrogate for survival in advanced colorectal cancer.

Authors:  Marc Buyse; Tomasz Burzykowski; Kevin Carroll; Stefan Michiels; Daniel J Sargent; Langdon L Miller; Gary L Elfring; Jean-Pierre Pignon; Pascal Piedbois
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

Review 10.  Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.

Authors:  Cornelis J A Punt; Marc Buyse; Claus-Henning Köhne; Peter Hohenberger; Roberto Labianca; Hans J Schmoll; Lars Påhlman; Alberto Sobrero; Jean-Yves Douillard
Journal:  J Natl Cancer Inst       Date:  2007-06-27       Impact factor: 13.506
View more
  5 in total

Review 1.  Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer.

Authors:  Weihong Sun; Changqing Jiang; Ying Ji; Chao Xiao; Haiping Song
Journal:  Biomed Res Int       Date:  2021-01-06       Impact factor: 3.411

Review 2.  Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.

Authors:  Sarah Ronnebaum; Abdalla Aly; Dipen Patel; Fernando Benavente; Juan-David Rueda
Journal:  Hepat Oncol       Date:  2021-08-26

3.  OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials.

Authors:  Khader Shameer; Youyi Zhang; Andrzej Prokop; Sreenath Nampally; Imran Khan A N; Jim Weatherall; Renee Bailey Iacona; Faisal M Khan
Journal:  JCO Clin Cancer Inform       Date:  2022-03

4.  The role of fructose 1,6-bisphosphate-mediated glycolysis/gluconeogenesis genes in cancer prognosis.

Authors:  Chien-Hsiu Li; Ming-Hsien Chan; Yu-Chan Chang
Journal:  Aging (Albany NY)       Date:  2022-04-11       Impact factor: 5.682

Review 5.  Master protocols in immuno-oncology: do novel drugs deserve novel designs?

Authors:  Luca Mazzarella; Stefania Morganti; Antonio Marra; Dario Trapani; Giulia Tini; Piergiuseppe Pelicci; Giuseppe Curigliano
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.